International Journal of Hematology

, Volume 92, Issue 5, pp 713–724

Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)

  • Michinori Ogura
  • Kuniaki Itoh
  • Tomohiro Kinoshita
  • Haruhiko Fukuda
  • Takeaki Takenaka
  • Tomoko Ohtsu
  • Yoshitoyo Kagami
  • Kensei Tobinai
  • Masataka Okamoto
  • Hideki Asaoku
  • Tsuneo Sasaki
  • Chikara Mikuni
  • Masami Hirano
  • Takaaki Chou
  • Kazunori Ohnishi
  • Hitoshi Ohno
  • Kaori Nasu
  • Kenichi Okabe
  • Shuichi Ikeda
  • Shigeo Nakamura
  • Tomomitsu Hotta
  • Masanori Shimoyama
Original Article

DOI: 10.1007/s12185-010-0712-8

Cite this article as:
Ogura, M., Itoh, K., Kinoshita, T. et al. Int J Hematol (2010) 92: 713. doi:10.1007/s12185-010-0712-8

Abstract

Although ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) therapy has been regarded as a standard of care for advanced-stage Hodgkin lymphoma (HL) since 1992, there has been no prospective data of ABVD therapy in Japan. To investigate the efficacy and safety of ABVd therapy with the lower dose of dacarbazine (250 mg/m2) in patients with newly diagnosed stage II–IV HL, Lymphoma Study Group of Japan Clinical Oncology Group conducted a phase II study. The primary endpoints were complete response rate (%CR) and progression-free survival (PFS). A total of 128 patients with age less than 70 years were enrolled and received 6–8 cycles of ABVd followed by radiation to initial bulky mass. The %CR in 118 eligible patients was 81.4% [95% confidence interval (CI) 73.1–87.9%]. Major toxicity was grade 4 neutropenia (45.3%). Grade 3 nausea/vomiting was the most frequent non-hematological toxicity (10.9%). Transient grade 4 constipation, infection (abscess), hypoxemia and hyperbilirubinemia were observed in 4 patients. No treatment-related death was observed. PFS and overall survival at 5 years were 78.4% (95% CI 70.9–85.9%) and 91.3% (95% CI 86.1–96.5%), respectively. In conclusion, ABVd is effective in Japanese patients with stage II–IV HL with acceptable toxicities (UMIN-CTR Number: C000000092).

Keywords

Hodgkin lymphomaChemotherapyABVd therapyPhase II study

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Michinori Ogura
    • 1
    • 18
  • Kuniaki Itoh
    • 2
  • Tomohiro Kinoshita
    • 3
  • Haruhiko Fukuda
    • 4
  • Takeaki Takenaka
    • 5
    • 19
  • Tomoko Ohtsu
    • 2
    • 20
  • Yoshitoyo Kagami
    • 1
    • 21
  • Kensei Tobinai
    • 5
  • Masataka Okamoto
    • 6
  • Hideki Asaoku
    • 7
  • Tsuneo Sasaki
    • 8
  • Chikara Mikuni
    • 9
    • 22
  • Masami Hirano
    • 6
  • Takaaki Chou
    • 10
  • Kazunori Ohnishi
    • 11
  • Hitoshi Ohno
    • 12
    • 23
  • Kaori Nasu
    • 13
    • 24
  • Kenichi Okabe
    • 14
    • 25
  • Shuichi Ikeda
    • 15
    • 26
  • Shigeo Nakamura
    • 16
    • 27
  • Tomomitsu Hotta
    • 17
    • 28
  • Masanori Shimoyama
    • 5
  1. 1.Department of Hematology and ChemotherapyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Division of Hematology and OncologyNational Cancer Center Hospital EastKashiwaJapan
  3. 3.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  4. 4.JCOG Data Center, Center for Cancer Control and Information ServicesNational Cancer CenterTokyoJapan
  5. 5.Hematology DivisionNational Cancer Center HospitalTokyoJapan
  6. 6.Department of MedicineFujita Health University School of MedicineToyoakeJapan
  7. 7.Department of HematologyHiroshima Red Cross HospitalHiroshimaJapan
  8. 8.Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  9. 9.Department of HematologySapporo National HospitalSapporoJapan
  10. 10.Department of Internal MedicineNiigata Cancer Center HospitalNiigataJapan
  11. 11.The 3rd Department of Internal MedicineHamamatsu University School of MedicineHamamatsuJapan
  12. 12.Department of Hematology and OncologyGraduate School of Medicine, Kyoto UniversityKyotoJapan
  13. 13.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  14. 14.Department of HematologyShikoku National HospitalMatsuyamaJapan
  15. 15.Department of HematologySasebo City General HospitalSaseboJapan
  16. 16.Department of PathologyAichi Cancer Center HospitalNagoyaJapan
  17. 17.Department of Hematology and OncologyTokai University School of MedicineIseharaJapan
  18. 18.Department of Hematology and OncologyNagoya Daini Red Cross HospitalNagoyaJapan
  19. 19.OhubuJapan
  20. 20.Bayer HealthCareBayer Schering PharmaTokyoJapan
  21. 21.Department of HematologyToyota Kosei HospitalToyotaJapan
  22. 22.Sapporo Yuushoukan HospitalSapporoJapan
  23. 23.Department of HematologyTakeda General HospitalKyotoJapan
  24. 24.Nasu Medical ClinicKyotoJapan
  25. 25.Kihoku Town HospitalKitauwagunJapan
  26. 26.Department of Internal MedicineHirado Municipal HospitalHiradoJapan
  27. 27.Department of PathologyNagoya University Graduate School of MedicineNagoyaJapan
  28. 28.National Hospital Organization, Nagoya Medical CenterNagoyaJapan